Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Albany Molecular Research, Oso Biopharm deal

    Albany Molecular Research Inc. (NASDAQ:AMRI), Albany, N.Y. Oso Biopharm Holdings LLC, Dover, Del. Business: Biomanufacturing Albany Molecular Research completed its acquisition of Oso Biopharms Oso Biopharmaceuticals …

    Published on 7/21/2014
  • Allergan, Valeant Pharmaceuticals deal

    Allergan Inc. (NYSE:AGN), Irvine, Calif. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Montreal, Quebec Business: Neurology, Dermatology, Ophthalmic Allergans largest shareholder, hedge fund Pershing …

    Published on 7/21/2014
  • AstraZeneca, MRC deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. MRC Technology, London, U.K. Business: Cancer, Endocrine/Metabolic, Inflammation AstraZeneca and MRC renewed for two years a 2010 deal granting MRC Technology scientists …

    Published on 7/21/2014
  • BioAlliance, EMS deal

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France EMS S.A., Sao Paulo, Brazil Business: Infectious BioAlliance granted EMS rights to commercialize Sitavig acyclovir Lauriad in Brazil. The mucoadhesive formulation of…

    Published on 7/21/2014
  • Boehringer Ingelheim, Hikma Pharmaceuticals deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany Hikma Pharmaceuticals plc (LSE:HIK), London, U.K. Business: Generics Hikma completed its acquisition of assets of the Bedford Laboratories U.S. generic injectables business …

    Published on 7/21/2014
  • Cell Source, Cell Source deal

    Cell Source Ltd., Tel Aviv, Israel Cell Source Inc. (OTCQB:CLCS), Las Vegas, Nev. Business: Transplant Cell Source Ltd. reverse-merged with Cell Source Inc. (formerly Ticket To See Inc.). Cell Source Ltd. shareholders …

    Published on 7/21/2014
  • Compugen, Bayer deal

    Compugen Ltd. (NASDAQ:CGEN;Tel Aviv:CGEN), Tel Aviv, Israel Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer Compugen said it will receive the first milestone payment under an August 2013 deal with Bayer to …

    Published on 7/21/2014
  • Cytori, U.S. Department of Health and Human Services deal

    Cytori Therapeutics Inc. (NASDAQ:CYTX;Xetra:XMPA), San Diego, Calif. U.S. Department of Health and Human Services, Washington, D.C. Business: Gene/Cell therapy, Other Cytori said it received preliminary notice of intent…

    Published on 7/21/2014
  • Eisai, Sarepta Therapeutics deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Musculoskeletal Sarepta disclosed that it is purchasing from Eisai a 60,000 square foot cGMP manufacturing …

    Published on 7/21/2014
  • Eli Lilly, Immunocore deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Immunocore Ltd., Abingdon, U.K. Business: Cancer Immunocore partnered with Eli Lilly to use Immunocures ImmTAC technology to discover and develop ImmTACs against three …

    Published on 7/21/2014
  • Endo, Dava deal

    Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Dava Pharmaceuticals Inc., Fort Lee, N.J. Business: Generics Endo will acquire generics company Dava for $575 million in cash up front. Dava is eligible to …

    Published on 7/21/2014
  • Fresenius, Novo deal

    Fresenius SE & Co. KGaA (Xetra:FRE;OTCQX:FSNUY), Bad Homburg, Germany Novo A/S, Hellerup, Denmark Business: Infectious, Supply/Service Xellia Pharmaceuticals, which is wholly owned by Novo, acquired the Raleigh, N.C., …

    Published on 7/21/2014
  • Hisamitsu, ANI Pharmaceuticals deal

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan ANI Pharmaceuticals Inc. (NASDAQ:ANIP), Baudette, Minn. Business: Neurology ANI acquired from Hisamitsus Noven Therapeutics LLC subsidiary the NDA for Lithobid…

    Published on 7/21/2014
  • Horizon Discovery, Stanford University deal

    Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Stanford University, Stanford, Calif. Business: Functional genomics Stanford granted gene-editing company Horizon non-exclusive, worldwide rights to IP related to …

    Published on 7/21/2014
  • IGI, Mallinckrodt deal

    IGI Laboratories Inc. (NYSE-M:IG), Buena, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Neurology Mallinckrodt granted IGI non-exclusive rights to launch a generic formulation of Pennsaid 1.5% diclofenac in…

    Published on 7/21/2014
  • Isis Pharmaceuticals, GlaxoSmithKline deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Endocrine/Metabolic Isis received a $1 million milestone payment from GlaxoSmithKline under an …

    Published on 7/21/2014
  • J&J, Genmab deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Cancer Genmab will receive a $25 million milestone payment from Johnson & Johnsons Janssen Biotech Inc. …

    Published on 7/21/2014
  • Knight Therapeutics, Sectoral Asset Management Inc. deal

    Knight Therapeutics Inc. (TSX:GUD), Westmount, Quebec Sectoral Asset Management Inc., Montreal, Quebec Business: Finance Knight invested $13 million into Sectoral Asset Managements New Emerging Medical Opportunities …

    Published on 7/21/2014
  • MDxHealth, Miraca deal

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Miraca Holdings Inc. (Tokyo:4544), Tokyo, Japan Business: Diagnostic MDxHealth granted Miracas Miraca Life Sciences Inc. subsidiary non-exclusive, co-promotion rights in …

    Published on 7/21/2014
  • Merck KGaA, Pharmstandard deal

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pharmstandard OJSC (RTS:PHST;LSE:PHST), Dolgoprudny, Russia Business: Autoimmune Pharmstandard will produce Rebif interferon beta-1a for multiple sclerosis (MS) from Mercks …

    Published on 7/21/2014
  • Merck, Santen deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan Business: Ophthalmic Santen completed its acquisition of rights from Merck to nine ophthalmic products in …

    Published on 7/21/2014
  • Miltenyi Biotec, Alfred Mann Institute deal

    Miltenyi Biotec GmbH, Bergisch Gladbach, Germany Alfred Mann Institute at the Technion Ltd., Haifa, Israel Business: Supply/Service The institutes Accellta Ltd. subsidiary granted Miltenyi Biotec non-exclusive, …

    Published on 7/21/2014
  • NanoCarrier, Eisai deal

    NanoCarrier Co. Ltd. (Tokyo:4571), Kashiwa, Japan Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisai granted NanoCarrier an exclusive, worldwide license to develop and commercialize Eisais E7974 for cancer…

    Published on 7/21/2014
  • NextCode, University College Dublin deal

    NextCode Health, Cambridge, Mass. University College Dublin, Dublin, Ireland Business: Neurology, Genomics NextCode granted the university a non-exclusive license to the companys Clinical Sequence Analyzer, Sequence …

    Published on 7/21/2014
  • Novartis, ProBioGen deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland ProBioGen AG, Berlin, Germany Business: Antibodies ProBioGen granted Novartis a non-exclusive license to use ProBioGens GlymaxX technology to enhance antibody-…

    Published on 7/21/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993